Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group
Heinz Zwierzina*, S. Suciu, J. Loeffler-Ragg, R. Neuwirtova, P. Fenaux, M. Beksac, J. Harousseau, V. Nuessler, J. Cermak, G. Solbu, R. Willemze, T. de Witte, S. Amadori, P. Stryckmans, D. Bron, A. Louwagie, D. Selleslag, M. Peetermans, Z. Berneman, B. CoiffierA. Thyss, J. H. Bourhis, D. Fière, R. Zittoun, J. P. Marie, D. Maraninchi, E. Baumelou, B. Lowenberg, P. Sonnenveld, H. Gerhartz, M. Ribeiro, I. Ben-Bassat, B. Labar, M. Dardenne
Research output: Contribution to journal › Article › peer-review
29Scopus
citations
Fingerprint
Dive into the research topics of 'Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/ macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: Final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group'. Together they form a unique fingerprint.